Strategic partnerships Potential collaborations with academic institutions and GMP manufacturing partners for clinical trial support and scalable production, as demonstrated by past collaborations with the University of Galway and Minaris to establish GMP processes.

Allogeneic platform Position LIFT’s allogeneic innate cell therapy as a differentiator in solid tumor immunotherapy to engage biotech and pharma buyers seeking off-the-shelf, antigen-independent approaches with scalable manufacturing.

Clinical pipeline Target partnerships or licensing discussions around first-in-class alpha neutrophil (IMANs) programs across multiple solid cancers, leveraging the preclinical stage and recent leadership appointments to accelerate clinical development.

Manufacturing readiness Emphasize the scalable production platform and GMP-ready processes to attract contract manufacturers and CROs for manufacturing, formulation, and supply chain support as clinical programs advance.

Financial and leadership signals Highlight recent funding and leadership appointments to signal growth momentum and governance stability, creating opportunities for investors, strategic partners, and senior advisory roles to accelerate commercialization.